IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1076-1100 out of 1241.

<< < 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 > >>

Public Release: 14-Nov-2013
Cell
A CNIO team discovers that senescence also plays a role in embryo development
A team of researchers from the Spanish National Cancer Research Centre in Madrid and another one from the Centre for Genomic Regulation in Barcelona have discovered, and are publishing in two articles in the journal Cell, that this switching-off mechanism also takes place in embryos, and not as a response to cell damage but as part the normal process of development.

Contact: Nuria Noriega
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)

Public Release: 13-Nov-2013
Environmental Science and Technology
BU study finds gymnasts' face high exposure to flame retardants
Competitive gymnasts have a higher exposure to potentially harmful flame-retardants than the general population, likely because such contaminants are present in foam used in gym equipment, a study led by Boston University School of Public Health researchers has found.
National Institute of Environmental Health Sciences

Contact: Lisa Chedekel
chedekel@bu.edu
617-571-6370
Boston University Medical Center

Public Release: 13-Nov-2013
Science Translational Medicine
Mystery explained: How a common chemo drug thwarts graft rejection in bone marrow transplants
Results of a Johns Hopkins study may explain why a chemotherapy drug called cyclophosphamide prevents graft-versus-host (GVHD) disease in people who receive bone marrow transplants. The experiments point to an immune system cell that evades the toxic effects of cyclophosphamide and protects patients from a lethal form of GVHD.
National Institutes of Health, NIH/National Cancer Institute, NIH/National Heart, Lung, and Blood Institute

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine

Public Release: 13-Nov-2013
New England Journal of Medicine
NIH study finds low-intensity therapy for Burkitt lymphoma is highly effective
Adult patients with a type of cancer known as Burkitt lymphoma had excellent long-term survival rates--upwards of 90 percent--following treatment with low-intensity chemotherapy regimens, according to a new clinical trial finding.
NIH/National Cancer Institute

Contact: NCI Office of Media Relations
ncipressofficers@mail.nih.gov
301-496-6641
NIH/National Cancer Institute

Public Release: 13-Nov-2013
Clinical Cancer Research
Finding antitumor T cells in a patient's own cancer
In a paper recently published in Clinical Cancer Research, investigators in the lab of Daniel Powell, Ph.D., at the Perelman School of Medicine, University of Pennsylvania, demonstrated for the first time that a T cell activation molecule can be used as a biomarker to identify rare antitumor T cells in human cancers. The molecule, CD137, is a protein that is not normally found on the surface of resting T cells but its expression is induced when the T cell is activated.
NIH/Nationcal Cancer Institute, Sandy Rollman Ovarian Cancer Foundation, Ovarian Cancer Research Fund

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine

Public Release: 13-Nov-2013
Cell Reports
Redesigned protein opens door for safer gene therapy
A fusion protein engineered by researchers at KU Leuven combining proteins active in HIV and Moloney murine leukaemia virus replication may lead to safer, more effective retroviral gene therapy.

Contact: Zeger Debyser
zeger.debyser@med.kuleuven.be
32-163-36332
KU Leuven

Public Release: 13-Nov-2013
Journal of Clinical Oncology
McMaster researchers test bandaging for swollen arm
As a complication of treatment, breast cancer patients may develop swelling in the arm, called lymphedema, which can last a long time. But there's no difference if simple compression bandages or a complicated daily lymphatic massage are used as treatment.
Canadian Breast Cancer Research Alliance, Juravinski Cancer Centre

Contact: Veronica McGuire
vmcguir@mcmaster.ca
90-552-591-402-2169
McMaster University

Public Release: 13-Nov-2013
Molecular Cell
Deletion of any single gene provokes mutations elsewhere in the genome
Johns Hopkins researchers report that the deletion of any single gene in yeast cells puts pressure on the organism's genome to compensate, leading to a mutation in another gene. Their discovery, which is likely applicable to human genetics because of the way DNA is conserved across species, could have significant consequences for the way genetic analysis is done in cancer and other areas of research, they say.
NIH/National Institute of Neurological Disorders and Stroke, NIH/National Institute of General Medical Sciences

Contact: Catherine Kolf
ckolf@jhmi.edu
443-287-2251
Johns Hopkins Medicine

Public Release: 13-Nov-2013
Nature
Northeastern researchers have discovered a new treatment to cure MRSA infection
Recent work from Northeastern University Distinguished Professor of Biology Kim Lewis promises to overcome one of the leading public health threats of our time. In a groundbreaking study published Wednesday in the journal Nature, Lewis' team presents a novel approach to treat and eliminate methicillin resistant Staphylococcus aureus, or MRSA, a potent bacterium whose resistance to antibiotics has kept it one step ahead of researchers. That is, until now.
NIH/National Institute of Allergy and Infectious Diseases IAA, EMSL, US Department of Energy/BER

Contact: Kara Shemin
kara.shemin@neu.edu
617-373-2802
Northeastern University

Public Release: 13-Nov-2013
Proceedings of the National Academy of Sciences
USC study reveals a protein that keeps people -- and their skeletons -- organized
Most people think that their planners or their iPhones keep them organized, when proteins such as liver kinase b1 actually have a lot more to do with it. New research from postdoctoral fellow Lick Lai in the lab of USC scientist Andy McMahon published in Proceedings of the National Academy of Sciences sheds light on how this important protein keeps people organized on a basic level by promoting orderly skeletal growth and preventing skeletal tumors.
NIH/National Institute of Diabetes and Digestive and Kidney Diseases

Contact: Cristy Lytal
lytal@med.usc.edu
University of Southern California - Health Sciences

Public Release: 12-Nov-2013
The Lancet
Tailored pre-transplant therapy boosts survival rate in rare immune deficiency
Chronic granulomatous disease is a rare immune deficiency that seriously compromises organ function and is life-threatening, with 20-30 percent of patients dying within the first two decades of life. Tailored doses of the pre-transplant drug therapy boosts survival rates to over 90 percent.

Contact: William Raillant-Clark
w.raillant-clark@umontreal.ca
514-343-7593
University of Montreal

Public Release: 12-Nov-2013
Cell Stem Cell
New discovery on early immune system development
Researchers at Lund University have shed light on how and when the immune system is formed, raising hope of better understanding various diseases in children, such as leukemia.

Contact: Charlotta Böiers
Charlotta.Boiers@med.lu.se
46-709-436-812
Lund University

Public Release: 12-Nov-2013
PLOS Medicine
Epigenetic silencing of the HAND2 tumor suppressor promotes endometrial cancer
A study published this week in PLOS Medicine suggests that epigenetic modification of the HAND2 gene plays a critical role in the development of endometrial cancer. HAND2 is active in the healthy endometrium (the tissue lining the uterus) where it antagonizes the growth-inducing effects of estrogen. By contrast, in more than 90 percent of endometrial cancers, the gene has undergone hypermethylation, an epigenetic modification that doesn't change its DNA sequence but renders it inactive.

Contact: Fiona Godwin
medicinepress@plos.org
PLOS

Public Release: 12-Nov-2013
PLOS ONE
Biomaterial-delivered chemotherapy could provide final blow to brain tumors
A polymer originally designed to help mend broken bones could be successful in delivering chemotherapy drugs directly to the brains of patients suffering from brain tumours, researchers at The University of Nottingham have discovered.
Brain Tumour Charity, University of Nottingham

Contact: Emma Thorne
emma.thorne@nottingham.ac.uk
44-011-595-15793
University of Nottingham

Public Release: 12-Nov-2013
Molecular Cancer Therapeutics
Controlling the hormonal environment in endometrial cancer sensitizes tumors to PARP inhibitors
Modulating the hormonal environment in which endometrial cancers grow could make tumors significantly more sensitive to a new class of drugs known as PARP inhibitors.
Concern Foundation, NIH/National Cancer Institute, UCLA's Scholars in Translational Medicine Program

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-794-0777
University of California - Los Angeles Health Sciences

Public Release: 12-Nov-2013
Lymphology
NYU researchers find a new solution in detecting breast-cancer related lymphedem
Doctors struggle to detect and diagnose breast-cancer related Lymphedema -- a condition affecting the lymphatic system and causing psychosocial distress and physical challenges for patients.
Avon Foundation, National Institutes of Health

Contact: Christopher James
christopher.james@nyu.edu
212-998-6876
New York University

Public Release: 12-Nov-2013
Thyroid
New ethics guidelines from American Thyroid Association published in Thyroid journal
In this changing era of health care delivery, physician guidelines on ethics are more important than ever. As each specialty area faces its own issues and dilemmas regarding patient care, scarcity of resources, and conflicts of interest, the American Thyroid Association has developed ethics guidelines specific to the field of thyroidology. These key guidelines are published in Thyroid, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 12-Nov-2013
Lancet Oncology
Clinical trial finds concurrent therapy not necessary to achieve high pathological in breast cancer
Clinical trial finds concurrent therapy is not necessary to achieve high pathological complete responses in breast cancer patients with HER-2-positive disease.

Contact: William Fitzgerald
wbfitzgerald@mdanderson.org
713-792-9518
University of Texas M. D. Anderson Cancer Center

Public Release: 12-Nov-2013
Nucleic Acids Research
Researcher finds potential new use for old drugs
A class of drugs used to treat parasitic infections such as malaria may also be useful in treating cancers and immune-related diseases, a new WSU-led study has found. Researchers discovered that simple modifications to the drug furamidine have a major impact on its ability to affect specific human proteins involved in the on-off switches of certain genes.
National Institutes of Health

Contact: Gregory Poon
gpoon@wsu.edu
509-335-8341
Washington State University

Public Release: 12-Nov-2013
Physics in Medicine and Biology
Balloon mis-positioning during prostate cancer treatment could affect success of radiation delivery
A University of Colorado Cancer Center study recently published in the journal Physics in Medicine and Biology shows that endorectal balloons commonly used during precise radiation treatment for prostate cancer can deform the prostate in a way that could make radiation miss its mark.

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver

Public Release: 12-Nov-2013
Journal of the National Cancer Institute
Deaths from pancreatic cancer rise, fall along racial lines
Pancreatic cancer death rates in whites and blacks have gone in opposite directions over the past several decades in the United States, with the direction reversing in each ethnicity during those years.

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society

Public Release: 11-Nov-2013
Annals of Family Medicine
November/December 2013 Annals of Family Medicine tip sheet
This tip sheet offers synopses of original research and commentary featured in the November/December 2013 issue of Annals of Family Medicine.

Contact: Angela Sharma
asharma@aafp.org
913-269-2269
American Academy of Family Physicians

Public Release: 11-Nov-2013
Cancer Cell
Study finds key link responsible for colon cancer initiation and metastasis
An ASU research team led by Biodesign Institute executive director Dr. Ray DuBois, M.D., Ph.D., has shown that a key genetic culprit, called CXCR2, is implicated in the tumor formation, growth and progression in a mouse model of colon cancer.

Contact: Joe Caspermeyer
joseph.caspermeyer@asu.edu
480-258-8972
Arizona State University

Public Release: 11-Nov-2013
Cancer
Young breast cancer patients with poorer financial status may experience delays in seeking care
Researchers who sought to determine why breast cancers are more deadly in young women found that only a minority of young women experience long delays between the time they detect a breast abnormality and the time they receive a diagnosis, but delays in seeking care are more common in women with fewer financial resources. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society.

Contact: Amy Molnar
sciencenewsroom@wiley.com
201-748-8844
Wiley

Public Release: 8-Nov-2013
Oncogene
Penn study identifies new trigger for breast cancer metastasis
For years, scientists have observed that tumor cells from certain breast cancer patients with aggressive forms of the disease contained low levels of mitochondrial DNA. But, until recently, no one was able to explain how this characteristic influenced disease progression. Now, University of Pennsylvania researchers have revealed how a reduction in mitochondrial DNA content leads human breast cancer cells to take on aggressive, metastatic properties.
National Institutes of Health, Harriet Ellison Woodward Trust

Contact: Katherine Unger Baillie
kbaillie@upenn.edu
215-898-9194
University of Pennsylvania

Showing releases 1076-1100 out of 1241.

<< < 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 > >>

  Search News Releases

     

 

 

EurekAlert!